[
 {
  "document": {
   "authors": "Farah Humayun",
   "contact_info": "farah.humayun@scai-extern.fraunhofer.de",
   "description": "Heme BEL model is a disease model based on Biological Expression Language(BEL) containing the core mechanisms of heme as modulator in Hemolytic diseases such as sickle-cell anemia, beta-thalassemia, malaria and autoimmune hemolytic anemia.",
   "licences": "MIT License",
   "name": "heme_27125525.bel",
   "version": "1.0.0"
  }
 },
 {
  "definitions": [
   {
    "namespace": {
     "keyword": "MGI",
     "type": "URL",
     "value": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "mgi",
     "type": "URL",
     "value": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "mgi",
     "type": "URL",
     "value": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "mgi",
     "type": "URL",
     "value": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "chebi",
     "type": "URL",
     "value": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "drugbank",
     "type": "URL",
     "value": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "ECCODE",
     "type": "URL",
     "value": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "HBP",
     "type": "URL",
     "value": "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/export/hbp-names.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "hgnc",
     "type": "URL",
     "value": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "HGNCGENEFAMILY",
     "type": "URL",
     "value": "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/external/hgnc.genefamily-names.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "go",
     "type": "URL",
     "value": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "interpro",
     "type": "URL",
     "value": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "MeSH",
     "type": "URL",
     "value": "https://raw.githubusercontent.com/pharmacome/terminology/01c9daa61012b37dd0a1bc962521ba51a15b38f1/external/mesh-names.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "mgi",
     "type": "URL",
     "value": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "mirbase",
     "type": "URL",
     "value": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/mirbase-names.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "ncbigene",
     "type": "URL",
     "value": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "pfam",
     "type": "URL",
     "value": "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "rgd",
     "type": "URL",
     "value": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/rgd-names.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "FPLX",
     "type": "URL",
     "value": "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "CTO",
     "type": "URL",
     "value": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/clinical-trial-ontology/clinical-trial-ontology-1.0.0.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "DO",
     "type": "URL",
     "value": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20170725.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "HP",
     "type": "URL",
     "value": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "SCOMP",
     "type": "URL",
     "value": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-named-complexes/selventa-named-complexes-20170725.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "SFAM",
     "type": "URL",
     "value": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-protein-families/selventa-protein-families-20170725.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "DBSNP",
     "type": "PATTERN",
     "value": "rs[0-9]+",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "TAXONOMY",
     "type": "PATTERN",
     "value": "^\\d+$",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "UNIPROT",
     "type": "PATTERN",
     "value": "^([A-N,R-Z][0-9]([A-Z][A-Z,0-9][A-Z,0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z,0-9][A-Z,0-9][A-Z,0-9][0-9])(\\.\\d+)?$",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "PUBCHEM",
     "type": "PATTERN",
     "value": "^\\d+$",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "HM",
     "type": "PATTERN",
     "value": ".*",
     "value_list": []
    }
   },
   {
    "annotation": {
     "keyword": "Species",
     "type": "PATTERN",
     "value": ".*",
     "value_list": []
    }
   },
   {
    "annotation": {
     "keyword": "TimePoint",
     "type": "PATTERN",
     "value": ".*",
     "value_list": []
    }
   },
   {
    "annotation": {
     "keyword": "Concentration",
     "type": "PATTERN",
     "value": ".*",
     "value_list": []
    }
   },
   {
    "annotation": {
     "keyword": "Anatomy",
     "type": "URL",
     "value": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
     "value_list": []
    }
   },
   {
    "annotation": {
     "keyword": "CellLine",
     "type": "URL",
     "value": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno",
     "value_list": []
    }
   },
   {
    "annotation": {
     "keyword": "CellStructure",
     "type": "URL",
     "value": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno",
     "value_list": []
    }
   },
   {
    "annotation": {
     "keyword": "Cell",
     "type": "URL",
     "value": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
     "value_list": []
    }
   },
   {
    "annotation": {
     "keyword": "Confidence",
     "type": "URL",
     "value": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
     "value_list": []
    }
   },
   {
    "annotation": {
     "keyword": "Disease",
     "type": "URL",
     "value": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
     "value_list": []
    }
   },
   {
    "annotation": {
     "keyword": "Gender",
     "type": "URL",
     "value": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno",
     "value_list": []
    }
   },
   {
    "annotation": {
     "keyword": "MeSHAnatomy",
     "type": "URL",
     "value": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
     "value_list": []
    }
   },
   {
    "annotation": {
     "keyword": "MeSHDisease",
     "type": "URL",
     "value": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno",
     "value_list": []
    }
   },
   {
    "annotation": {
     "keyword": "Subgraph",
     "type": "URL",
     "value": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno",
     "value_list": []
    }
   },
   {
    "annotation": {
     "keyword": "TextLocation",
     "type": "URL",
     "value": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno",
     "value_list": []
    }
   }
  ]
 },
 {
  "statements_and_sets": [
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "Stroke. 2016 Jun;47(6):1626-31. doi: 10.1161/STROKEAHA.116.013146. Epub 2016 Apr 28.",
       "ref": "27125525",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "TextLocation": [
        "Introduction"
       ]
      }
     },
     {
      "evidence": "Hematoma resolution occurs in the days after intracerebral hemorrhage(ICH)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Cerebral Hemorrhage"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Hematoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "evidence": "The hematoma clearance may be via red blood cell(RBC) lysis or phagocytosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Phagocytosis"
        }
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Hematoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "evidence": "Erythrocyte lysis after ICH can be mediated by the complement activation and formation of the membrane attack complex(MAC), which contains complement C5b, C6, C7, C8 and C9 proteins(C5b 9)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "complement activation"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Hemolysis"
        }
       ]
      ]
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Complement Membrane Attack Complex"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Hemolysis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "set": {
       "TextLocation": [
        "Results"
       ]
      }
     }
    ]
   },
   {
    "sets": [
     {
      "evidence": "We found that diameter of RBC decreased gradually in the hematoma edge and hematoma center(e.g. day-3 at hematoma edge:2.71 0.38m vs. 3.89 0.35m at 4 hours,p<0.01; hematoma center:2.61 0.29 m vs. 3.75 0.25m at 4 hours,p<0.01. Fig. 1)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Hematoma"
        }
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Erythrocyte Indices"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "evidence": "The level of hemoglobin declined gradually over the time after the onset of ICH with a significant reduction at day 3. The contents of hemoglobin in the clot were 26.2  5.2 mg/g at 4 hours, but were reduced to 13.9  0.9 mg/g at day-3 (Fig. 2B,p<0.01)."
     },
     {
      "set": {
       "MeSHDisease": [
        "Cerebral Hemorrhage"
       ]
      }
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Hematoma"
        }
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HBB"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "evidence": "Activation of the complement system and the formation of MAC resulted in an increased membrane permeability and erythrocyte lysis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "complement activation"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Hemolysis"
        }
       ]
      ]
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "complement activation"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Cell Membrane Permeability"
        }
       ]
      ]
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Complement Membrane Attack Complex"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Hemolysis"
        }
       ]
      ]
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Complement Membrane Attack Complex"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Cell Membrane Permeability"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "evidence": "In this present study, MAC contents in the clot gradually increased with a marked accumulation at day-3 (53.5 8.2 vs. 11.0 3.9 ng/g at 4 hour,p<0.01,Fig. 2C) and stayed at high levels at day 7."
     },
     {
      "set": {
       "MeSHDisease": [
        "Cerebral Hemorrhage"
       ]
      }
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Hematoma"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Complement Membrane Attack Complex"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "evidence": "Erythrophagocytosis was observed in the hematoma edge at day-3 (Fig. 3A), and hemosiderin deposition was identifiable in the hematoma edge at day-7 (Fig. 3A)."
     },
     {
      "set": {
       "TimePoint": [
        "3 days"
       ]
      }
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Hematoma"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "HM",
         "name": "erythrophagocytosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "set": {
       "TimePoint": [
        "1 week"
       ]
      }
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Hematoma"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Hemosiderin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "evidence": "CD163 and HO-1 positive cells infiltrated into the hematoma from edge to center after ICH(Figs. 4A & 4B). A significant increase of CD163 cells was found at day 3."
     },
     {
      "set": {
       "TimePoint": [
        "3 days"
       ]
      }
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Hematoma"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "CD163"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "evidence": "HO-1 protein levels in the hematoma also increased at day-3 (HO-1/GAPDH:0.65 0.08 at day-3 vs. 0.04 0.01 at 4 hour,p<0.01)."
     },
     {
      "set": {
       "TimePoint": [
        "3 days"
       ]
      }
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Hematoma"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMOX1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "evidence": "We found that hemoglobin contents in hematoma were significantly higher in the DFX treated group compare to the vehicle-treated group(15.9 1.8 vs. 11.8 0.8 mg/g,p<0.05,Fig. 5A)."
     },
     {
      "set": {
       "MeSHDisease": [
        "Cerebral Hemorrhage"
       ]
      }
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Hematoma"
        }
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HBB"
        }
       ]
      ]
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "desferrioxamine B"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HBB"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "evidence": "DFX also reduced the MAC content in the clot at day-3 (33.0 6.6 vs. 56.2 9.2 ng/g in the vehicle-treated group,p<0.05,Fig. 5B)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "desferrioxamine B"
        }
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Complement Membrane Attack Complex"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "evidence": "These results suggested that the treatment of DFX reduced the process of hemolysis after ICH, which might be due to alleviating MAC formation."
     },
     {
      "set": {
       "MeSHDisease": [
        "Cerebral Hemorrhage"
       ]
      }
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "desferrioxamine B"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Hemolysis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "evidence": "The loss of CD47 in the clot was reduced significantly by DFX treatment at day 3 (CD47/GAPDH:1.32 0.16 in ICH+DFX group vs. 0.74 0.07 in ICH + vehicle group,p<0.05,Fig. 5C) and day 7 (p<0.01,Suppl Figure I)."
     },
     {
      "set": {
       "TimePoint": [
        "3 days"
       ]
      }
     },
     {
      "set": {
       "MeSHDisease": [
        "Cerebral Hemorrhage"
       ]
      }
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "desferrioxamine B"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "CD47"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "evidence": "DFX treatment also caused a significant reduction in infiltrating CD163-positive and HO-1 positive cell in the hematoma at day 3 (Figs. 6A and B) and day 7 (Suppl Figures II & III)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "desferrioxamine B"
        }
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "CD163"
        }
       ]
      ]
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "desferrioxamine B"
        }
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMOX1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "evidence": "Western blot analysis showed that the protein expression of HO-1 was decreased in the hematoma in the DFX treated group at day 3(HO-1/GAPDH:0.32 0.04 vs. 0.98 0.07 in the vehicle-treated group,p<0.05,Fig. 6B) and day 7 (p<0.05,Suppl Figure III)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "desferrioxamine B"
        }
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMOX1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "set": {
       "TextLocation": [
        "Discussion"
       ]
      }
     },
     {
      "evidence": "The diameter of RBCs within the hematoma decreased with time after ICH."
     },
     {
      "set": {
       "MeSHDisease": [
        "Cerebral Hemorrhage"
       ]
      }
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Hematoma"
        }
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Erythrocyte Indices"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "evidence": "Following complement cascade activation, MAC on the cell membrane forms a pore resulting in membrane permeability changes17 finally leading to RBC morphological alterations and erythrocyte lysis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Complement Membrane Attack Complex"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Cell Membrane Permeability"
        }
       ]
      ]
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Complement Membrane Attack Complex"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Hemolysis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "evidence": "The current study examined the natural time course of CD47 expression in the hematoma in a swine ICH model and found that CD47 levels in the clot decrease with time."
     },
     {
      "set": {
       "MeSHDisease": [
        "Cerebral Hemorrhage"
       ]
      }
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Hematoma"
        }
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "CD47"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "evidence": "CD47 exerts its inhibitory effect on phagocytosis through binding to inhibitory immunoreceptor SIRP expressed by microglia/macrophages 21.Thus, the CD47-SIRP constitutes a negative feedback for erythrophagocytosis22."
     },
     {
      "set": {
       "Cell": [
        "macrophage"
       ]
      }
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "list",
         "name": "complex"
        }
       },
       [
        [
         [
          {
           "function": {
            "type": "abundance",
            "name": "protein"
           }
          },
          [
           {
            "namespace": "HGNC",
            "name": "CD47"
           }
          ]
         ],
         [
          {
           "function": {
            "type": "abundance",
            "name": "protein"
           }
          },
          [
           {
            "namespace": "HGNC",
            "name": "SIRPA"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "HM",
         "name": "erythrophagocytosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "evidence": "Our recent study showed that depleting CD47 in RBCs resulted in faster hematoma clearance with microglia/ macrophages being less likely to phagocytize RBCs with CD47 than CD47-deficient RBC 7."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "CD47"
        }
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Hematoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "evidence": "Evidence suggested that CD163 acts as a hemoglobin scavenger receptor on microglia/macrophage with a role in erythrophagocytosis."
     },
     {
      "set": {
       "Cell": [
        "macrophage"
       ]
      }
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "CD163"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "HM",
         "name": "erythrophagocytosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "evidence": "CD163 mediated hemoglobin/hematoma clearance is involved in the induction of HO-1, a rate-limiting enzyme for heme degradation 26."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "CD163"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMOX1"
        }
       ]
      ]
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMOX1"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "transformation",
         "name": "degradation"
        }
       },
       [
        [
         {
          "function": {
           "type": "abundance",
           "name": "abundance"
          }
         },
         [
          {
           "namespace": "CHEBI",
           "name": "heme"
          }
         ]
        ]
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "evidence": "A recent study, however, indicated that HO-1 is associated with blood clearance by enhancing erythrophagocytosis after stroke."
     },
     {
      "set": {
       "MeSHDisease": [
        "Stroke"
       ]
      }
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMOX1"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "HM",
         "name": "erythrophagocytosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "evidence": "The present study found that DFX treatment reduces MAC formation in the clot."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "desferrioxamine B"
        }
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Complement Membrane Attack Complex"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "evidence": "DFX also reduced CD47 loss and microglia/macrophage infiltration after ICH suggesting it also affects erythrophagocytosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "desferrioxamine B"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "CD47"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "evidence": "In combination, these finding may underlie our previous results showing that DFX slows hematoma resolution after ICH in aged rats 12."
     },
     {
      "set": {
       "MeSHDisease": [
        "Cerebral Hemorrhage"
       ]
      }
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "desferrioxamine B"
        }
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Hematoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "unset": [
       "TextLocation"
      ]
     }
    ]
   }
  ]
 }
]